Related Experiment Video
Updated: Jun 20, 2026
04:40
Venous Thrombosis Assay in a Mouse Model of Cancer
Published on: January 5, 2024
Venous thromboembolism in the hematologic malignancies.
Anna Falanga1, Marina Marchetti
1Division of Immunohematology and Transfusion Medicine, Department of Oncology/Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy. annafalanga@yahoo.com
Summary
Patients with blood cancers face high risks of blood clots. This review examines venous thromboembolism (VTE) in leukemia, lymphoma, and multiple myeloma, highlighting the need for better prevention and treatment strategies.
Area of Science:
- Hematology
- Oncology
- Thrombosis
Background:
- Patients with hematologic malignancies have a high risk of thrombotic and hemorrhagic complications.
- The incidence of these events is variable, influenced by disease type, chemotherapy, and central venous devices.
- Tumor cell biology and oncogenes can contribute to hypercoagulability in these patients.
Purpose of the Study:
- To review the epidemiology, pathogenesis, and management of venous thromboembolism (VTE) in acute leukemia, lymphomas, and multiple myeloma (MM).
- To highlight the current lack of routine thromboprophylaxis recommendations, except for MM.
- To emphasize the need for prospective clinical trials to guide VTE management in hematologic malignancies.
Main Methods:
- Literature review focusing on epidemiology, pathogenesis, and VTE management.
- Analysis of existing data on venous thromboembolism (VTE) incidence in specific hematologic malignancies.
- Synthesis of information regarding risk factors and biological mechanisms contributing to thrombosis.
Main Results:
- Venous thromboembolism (VTE) incidence varies across acute leukemia, lymphomas, and multiple myeloma (MM).
- Clinical risk factors and tumor cell biology play significant roles in thrombotic complications.
- Current guidelines lack routine thromboprophylaxis recommendations for most hematologic malignancies, with an exception for MM.
Conclusions:
- Hematologic malignancies present a significant risk for venous thromboembolism (VTE).
- Further research, including large randomized trials, is essential for establishing optimal thromboprophylaxis and treatment strategies.
- Understanding the interplay between cancer biology and coagulation is crucial for improving patient outcomes.
Related Concept Videos
01:30Venous Thrombosis IV: Nursing Management
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
01:30Venous Thrombosis I: Introduction
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:24Disorders of Hemostasis
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
01:19Pulmonary Embolism I: Introduction
A blood clot, or thrombus, is a semi-solid mass composed of fibrin, platelets, and red blood cells. When it forms within a vessel, it can obstruct blood flow, known as thrombosis. If part of the clot detaches, it becomes an embolus that can travel and block distant vessels. When this occurs in the pulmonary arteries, it causes a condition known as pulmonary embolism (PE).Origin and ImpactMost often, the embolus originates from a thrombus in the deep veins of the lower limbs, a condition called...
01:29Pulmonary Embolism I: Introduction
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...